在多发性硬化症中使用改变病情的治疗方法：英国神经病学家协会（ABN）2024指南。

IF 2.4 Q2 CLINICAL NEUROLOGY

PRACTICAL NEUROLOGY Pub Date : 2024-11-11 DOI:10.1136/pn-2024-004228

Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, Tarunya Arun, Anisha Doshi, Nikos Evangelou, Helen L Ford, Jeremy Hobart, Saiju Jacob, Paolo Antonio Muraro, Katy Murray, Jacqueline Palace, Ruth Dobson

{"title":"在多发性硬化症中使用改变病情的治疗方法：英国神经病学家协会（ABN）2024指南。","authors":"Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, Tarunya Arun, Anisha Doshi, Nikos Evangelou, Helen L Ford, Jeremy Hobart, Saiju Jacob, Paolo Antonio Muraro, Katy Murray, Jacqueline Palace, Ruth Dobson","doi":"10.1136/pn-2024-004228","DOIUrl":null,"url":null,"abstract":"The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.","PeriodicalId":39343,"journal":{"name":"PRACTICAL NEUROLOGY","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.\",\"authors\":\"Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, Tarunya Arun, Anisha Doshi, Nikos Evangelou, Helen L Ford, Jeremy Hobart, Saiju Jacob, Paolo Antonio Muraro, Katy Murray, Jacqueline Palace, Ruth Dobson\",\"doi\":\"10.1136/pn-2024-004228\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.\",\"PeriodicalId\":39343,\"journal\":{\"name\":\"PRACTICAL NEUROLOGY\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PRACTICAL NEUROLOGY\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/pn-2024-004228\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PRACTICAL NEUROLOGY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/pn-2024-004228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

英国神经病学家协会最近一次发布多发性硬化症（MS）疾病修饰治疗（DMT）指南是在 2015 年。从那时起，更多的 DMT 获得了许可，并被批准在国民健康服务中开具用于复发缓解型多发性硬化症、早期原发性进展型多发性硬化症和活动性继发性进展型多发性硬化症的处方。本更新指南提供了基于共识的 DMTs 使用方法。我们就以下方面提出了建议：DMTs 的资格、起始、监测、转换和停药；妊娠；公平获得 DMT；自体造血干细胞移植；以及非专利药的使用。我们强调了现有的最佳实践，并讨论了未来的优先事项。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.

The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

PRACTICAL NEUROLOGY Medicine-Neurology (clinical)

CiteScore

3.70

自引率

3.60%

发文量

113

期刊介绍： The essential point of Practical Neurology is that it is practical in the sense of being useful for everyone who sees neurological patients and who wants to keep up to date, and safe, in managing them. In other words this is a journal for jobbing neurologists - which most of us are for at least part of our time - who plough through the tension headaches and funny turns week in and week out. Primary research literature potentially relevant to routine clinical practice is far too much for any neurologist to read, let alone understand, critically appraise and assimilate. Therefore, if research is to influence clinical practice appropriately and quickly it has to be digested and provided to neurologists in an informative and convenient way.